Lexaria Bioscience Corp (LEXX) Stock Price, Quote & News

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 765 6424

Website: lexariabioscience.com

Address:

740 McCurdy Road, Suite 100, Kelowna, Canada

Makingmillions192 Jul. 20 at 1:14 AM

$LEXX The tape doesn't lie—that daily chart looks beautiful. When a micro-cap with a tiny float has an accumulation spike like this on zero news, it means the market is front-running the data. And yes, last week was a volume accumulation spike which initiated a trend reversal. Here are the technical overhead levels where this pre-news melt-up can realistically head over the next few weeks before the data officially drops: Target 1: $0.75 - $0.80 (The Immediate Gap Fill) 🤝 Target 2: $1.00 (The Psychological "Compliance" Magnet) 🔥 The trend has officially flipped to bullish—enjoy the run up heading into news!!! Things could get interesting really quick with our small float and catalyst train on the way 🚂 💨 📈

0 · Reply

Makingmillions192 Jul. 19 at 7:10 PM

$LEXX Trend reversal confirmation “Let’s jump on our white horses and go for a bullish ride. Today’s candlestick has a white body and its close is above the confirmation level. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. The trend is also bullish and perhaps it is the right time to participate in bullish fervor. The market is signaling a potential new profit opportunity. Capitalize on this bullish opportunity without hesitation.” Melt up until data drops in Aug 🌋 💰 🧨 $SLS $RANI $VRTX $EDSA

0 · Reply

Hakapeszi Jul. 18 at 3:06 PM

$RANI It is perfectly normal that everyone is biased with its preferred stock ($RANI ; $LEXX). I think both can succeed despite its common target in the obesity market. Let me just share my assessment regarding the mentioned cons against RANI. But first of all, one should not forget, RANI addresses the whole biologics market of ca. $600 billion, currently administered almost entirely via injections. The market is expending and can double in 10 years. “Patient Nightmare” 😊 . I wouldn’t call it a nightmare, but the inconvenience is the injection that could be replaced by an oral pill. The microneedle is not a metal one, but a dissolvable sugar needle which is injected into the small intestine tissue. Important: the lining of the small intestine is the most regenerative tissue in humans! Even if (by chance) the weekly administered Ranipill was injected perfectly at the same point, the intestine would have regenerated by then.

1 · Reply

Makingmillions192 Jul. 17 at 8:02 PM

$LEXX Great days lads!!! Reversal confirmed 🍻 The firework show is nearing 🧨 Have a great weekend!!!

0 · Reply

Makingmillions192 Jul. 17 at 8:01 PM

$LEXX Dosing done on Sunday - data drops starting next month ✅

0 · Reply

ZacksSCR Jul. 17 at 7:55 PM

$LEXX: Dosing Started for Animal & Human GLP-1 Studies https://buff.ly/0UHbVwA

0 · Reply

Makingmillions192 Jul. 17 at 7:37 PM

$LEXX Volume starting to pick up 👀 let’s go boys 🚀

0 · Reply

Makingmillions192 Jul. 17 at 7:19 PM

$LEXX $RANI Comparing RANI to LEXX fundamentally misunderstands the physics of oral drug delivery: 1. The Patient Nightmare: Rani's "Pill" is a complex robotic device that literally injects a needle into the intestinal wall. Good luck selling patients on an auto-injector in their stomach over a simple, smooth DehydraTECH tablet. 2. Manufacturing & Cost Moat: Rani's complex mechanical pills are incredibly expensive and difficult to scale. LEXX applies standard, low-cost formulation tech to commoditized APIs. 3. The M&A Play: Big Pharma wants scalable orals, not complex micro-robotics. BUT I wish goodluck to both 🙏 $LLY $VKTX $NVO

1 · Reply

Mandalo Jul. 17 at 7:15 PM

$RANI RANI consistently commands stronger investor sentiment thanLEXX, primarily driven by superior institutional validation and clinical focus. While both target innovative drug delivery, the market heavily favors Rani’s strategic position: Big Pharma Backing: Rani’s partnerships with giants like Sanofi and Pfizer provide massive credibility that $LEXX currently lacks. Pure-Play Biotech: Rani’s focus on converting high-barrier injectable biologicals into oral pills ($RANI Pill) attracts serious institutional capital. Legacy Discount: Lexaria’s DehydraTECH is promising for GLP-1s, but its historical cannabis/CBD roots still cap its appeal among traditional biotech investors. Ultimately, RANI enjoys higher liquidity and trust, whileLEXX remains a more volatile, retail-driven speculative play. 😇🤑👍

1 · Reply

Makingmillions192 Jul. 17 at 7:00 PM

$LEXX Bids stacking now and ask is light…. Could see a breakout at any time 👀 🚀 Let the melt-up begin

0 · Reply

Lexaria Bioscience Quarterly report: Q3 2026

Jul 6, 2026, 9:10 AM EDT - 13 days ago

Lexaria Updates Business Development

2026-06-25T13:15:18.000Z - 24 days ago

Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing

NVO

Jun 25, 2026, 9:10 AM EDT - 24 days ago

Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Jun 25, 2026, 9:10 AM EDT - 24 days ago

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

2026-06-23T15:26:36.000Z - 26 days ago

Lexaria Bioscience begins dosing in animal study GLP-1-A26-1

Jun 23, 2026, 9:25 AM EDT - 26 days ago

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Jun 23, 2026, 9:25 AM EDT - 26 days ago

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

2026-06-17T13:42:22.000Z - 4 weeks ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Jun 17, 2026, 9:25 AM EDT - 4 weeks ago

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Jun 17, 2026, 9:25 AM EDT - 4 weeks ago

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

2026-06-09T13:34:05.000Z - 5 weeks ago

Lexaria announces dosing completion in 2026 Animal Study 2

Jun 9, 2026, 9:25 AM EDT - 5 weeks ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Jun 9, 2026, 9:25 AM EDT - 5 weeks ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Jun 3, 2026, 9:25 AM EDT - 6 weeks ago

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Jun 3, 2026, 9:25 AM EDT - 6 weeks ago

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program

May 27, 2026, 7:00 AM EDT - 7 weeks ago

Lexaria Bioscience Slides: Corporate presentation

2026-05-19T13:27:07.000Z - 2 months ago

Lexaria Bioscience announces ethics approval for Human Pilot Study 7

NVO

May 19, 2026, 9:15 AM EDT - 2 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

May 7, 2026, 9:25 AM EDT - 2 months ago

Lexaria Bioscience Releases Second Episode of Investor Video Series

2026-05-05T13:24:25.000Z - 2 months ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO

May 5, 2026, 9:10 AM EDT - 2 months ago

Lexaria Updates Progress on Human Study #7

May 1, 2026, 9:25 AM EDT - 2 months ago

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

2026-04-29T13:16:24.000Z - 2 months ago

Lexaria Bioscience extends material transfer agreement with pharma company

Apr 29, 2026, 9:10 AM EDT - 2 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2026-04-23T13:23:01.000Z - 3 months ago

Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs

Apr 23, 2026, 9:05 AM EDT - 3 months ago

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

2026-04-21T15:02:42.000Z - 3 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Apr 21, 2026, 9:10 AM EDT - 3 months ago

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

2026-04-15T13:24:10.000Z - 3 months ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Apr 15, 2026, 9:10 AM EDT - 3 months ago

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Lexaria Bioscience Quarterly report: Q2 2026

2026-04-07T13:40:33.000Z - 3 months ago

Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval

LLY

Apr 7, 2026, 9:10 AM EDT - 3 months ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

2026-04-01T13:26:48.000Z - 3 months ago

Lexaria Bioscience to begin new human clinical study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 3 months ago

Lexaria to Begin New Human Clinical Study in GLP-1

2026-03-26T13:25:26.000Z - 4 months ago

Lexaria receives five new patents, including two for diabetes treatment

Mar 26, 2026, 9:20 AM EDT - 4 months ago

Lexaria's Robust Patent Portfolio Continues to Grow

Mar 24, 2026, 9:15 AM EDT - 4 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

2026-03-04T14:39:22.000Z - 4 months ago

Lexaria Bioscience announces 2026 R&D plans

Mar 4, 2026, 9:25 AM EST - 4 months ago

Lexaria Announces New R&D Plans for 2026

2026-02-05T14:25:56.000Z - 5 months ago

Lexaria announces final results from GLP-1-H25-5 study

Feb 5, 2026, 9:15 AM EST - 5 months ago

Lexaria Announces Positive Final Results From Human Pilot Study #5

2026-01-22T14:25:16.000Z - 6 months ago

Lexaria Bioscience awarded six additional patents

Jan 22, 2026, 9:20 AM EST - 6 months ago

Lexaria Awarded Six Additional Patents

Jan 13, 2026, 7:00 AM EST - 6 months ago

Lexaria Bioscience Quarterly report: Q1 2026

2026-01-12T14:50:08.000Z - 6 months ago

Lexaria CEO says ‘closer to a commercial breakthrough than ever before’

Jan 12, 2026, 9:10 AM EST - 6 months ago

Lexaria Releases Annual Letter from the CEO

2025-12-30T14:25:09.000Z - 7 months ago

Lexaria releases additional results from Phase 1b study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 7 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

2025-12-29T22:25:07.000Z - 7 months ago

Lexaria Bioscience files to sell 2.75M shares of common stock for holders

Dec 29, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Registration statement: Registration filing

Dec 23, 2025, 9:29 AM EST - 7 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025, 4:00 PM EST - 7 months ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 7 months ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Proxy statement: Proxy filing

Dec 5, 2025, 7:00 AM EST - 8 months ago

Lexaria Bioscience Registration statement: Registration filing

Nov 28, 2025, 7:00 AM EST - 8 months ago

Lexaria Bioscience Annual report: Q4 2025

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Lexaria Bioscience Registration statement: Registration filing

Oct 9, 2025, 9:20 AM EDT - 10 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025, 4:30 PM EDT - 10 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 10 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025, 11:20 AM EDT - 10 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 14, 2025, 9:20 AM EDT - 1 year ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025, 9:20 AM EDT - 1 year ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 28, 2025, 9:25 AM EDT - 1 year ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 23, 2025, 9:25 AM EDT - 1 year ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q3 2025

May 12, 2025, 9:00 AM EDT - 1 year ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 23, 2025, 9:10 AM EDT - 1 year ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q2 2025

Apr 3, 2025, 9:10 AM EDT - 1 year ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Makingmillions192 Jul. 20 at 1:14 AM

0 · Reply

Makingmillions192 Jul. 19 at 7:10 PM

0 · Reply

Hakapeszi Jul. 18 at 3:06 PM

1 · Reply

Makingmillions192 Jul. 17 at 8:02 PM

$LEXX Great days lads!!! Reversal confirmed 🍻 The firework show is nearing 🧨 Have a great weekend!!!

0 · Reply

Makingmillions192 Jul. 17 at 8:01 PM

$LEXX Dosing done on Sunday - data drops starting next month ✅

0 · Reply

ZacksSCR Jul. 17 at 7:55 PM

$LEXX: Dosing Started for Animal & Human GLP-1 Studies https://buff.ly/0UHbVwA

0 · Reply

Makingmillions192 Jul. 17 at 7:37 PM

$LEXX Volume starting to pick up 👀 let’s go boys 🚀

0 · Reply

Makingmillions192 Jul. 17 at 7:19 PM

1 · Reply

Mandalo Jul. 17 at 7:15 PM

1 · Reply

Makingmillions192 Jul. 17 at 7:00 PM

$LEXX Bids stacking now and ask is light…. Could see a breakout at any time 👀 🚀 Let the melt-up begin

0 · Reply

Makingmillions192 Jul. 17 at 6:56 PM

$LEXX The GLP-1 sector has hit a bottleneck: weight-loss efficacy is topping out. The next multi-billion-dollar battleground isn't superior potency—it is drug tolerability and patient compliance. This paradigm shift is why the industry is locked onto Lexaria Bioscience ($LEXX). The active 5-week patient dosing window for Study #7 officially concludes this weekend on July 19, 2026, moving the trial directly to data unblinding. A successful trial alters the metabolic health landscape in three ways: Bypasses the SNAC Monopoly: It offers a highly absorbable oral delivery alternative that eliminates the rigid fasting windows and erratic absorption common to traditional SNAC carrier systems. Targets a ~40% Side Effect Reduction: Could trigger M&A Activity: It transforms an asset-light, virtual R&D platform into a deeply de-risked, highly lucrative licensing asset for Big Pharma suitors actively hunting for advanced oral tech. Exciting times 💊 🚀 $LLY $NVO $AMGN $PFE

1 · Reply

Makingmillions192 Jul. 17 at 5:49 PM

$LEXX Looks like we could get a centreline daily candle MACD cross today which would confirm a trend reversal and validate the melt-up theory before data drops. Hit the ask gentlemen 🫡

0 · Reply

Makingmillions192 Jul. 17 at 5:27 PM

$LEXX A little serious buying volume and this will fly. Ask is light

0 · Reply

Makingmillions192 Jul. 17 at 5:07 PM

$LEXX Looking good on the technical side, in for 8k so far today. We continue buying into EOD. Last day of trading before Human study #7 completes. Very exciting

0 · Reply

The_Wealth_Maker Jul. 17 at 3:36 PM

$LEXX 😎

0 · Reply

Makingmillions192 Jul. 16 at 6:56 PM

$LEXX Big news!!! 🚨 ‼️ Novo Nordisk Receives EU Approval for Oral Wegovy $NVO This makes it the first oral GLP-1 approved for weight management in the European Union. This is a definitive, regulatory declaration that the future of GLP-1 is oral. Novo Nordisk's CEO openly stated, "For many people, a tablet may be a simpler and more acceptable way to start and continue treatment." To make oral semaglutide absorbable, Novo Nordisk relies on a massive dose of an absorption enhancer called SNAC. However, SNAC-based absorption is notoriously erratic, requiring patients to fast and take the pill with restricted water. If Lexaria's Human Study #7 (dropping in late August) proves that DehydraTECH achieves superior absorption over standard tablets with lower doses and better tolerability, they possess the key to optimizing the very product the EU just approved. https://www.reuters.com/legal/litigation/novo-nordisk-wins-eu-approval-wegovy-weight-loss-pill-2026-07-15/ $LLY $PFE $VKTX

0 · Reply

Makingmillions192 Jul. 16 at 6:44 PM

$LEXX 🚨 Cluster buys happening at the moment 🚨 Either accumulation or short covering atm Regardless great sign 👍 Place your buys boys she’s getting ready to move up $LLY $AMGN $RANI

0 · Reply

Makingmillions192 Jul. 16 at 6:20 PM

$LEXX Nice vol and accumulation today 💪 When this pops it’s going to be epic 🧨

0 · Reply

Makingmillions192 Jul. 16 at 4:27 PM

$LEXX Bought another 15k so far today

0 · Reply

paolo73 Jul. 16 at 4:11 PM

$LEXX Has anyone read the 10-Q from July 13th? Cash is running low, and they’ll soon need to raise capital to keep going. The only way I see that happening is by selling shares, because if there were any offers from partners or other types of financing, they would have announced it by now. The MTA listing has been pushed back to the end of the year... I just hope the capital raise happens at a higher price so I can get out of this lousy company.

0 · Reply

Makingmillions192 Jul. 16 at 2:35 PM

$LEXX Perfect time to start dropping big news as money rotates out of tech and semiconductors into areas of the market like Healthcare & Biotech $XBI $IBB $IYH

0 · Reply

Makingmillions192 Jul. 15 at 10:19 PM

$LEXX LEXARIA (LEXX) LATE-SUMMER DATA DROP SCHEDULE 🚀 • Mid-August 2026 - Study: Animal Study #2 (GLP-1-A26-2) What Big Pharma is Watching: First-ever compatibility and pharmacokinetic (PK) data evaluating DehydraTECH with tomorrow's multi-agonist blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. • Late August / Early September 2026. Study: Human Study #7 (GLP-1-H26-7) THE MAIN EVENT: Head-to-head, 5-week steady-state human data comparing DehydraTECH-semaglutide (tablet & capsule) directly against commercial Wegovy. Pharma is laser-focused on bio-absorption and a projected ~40% reduction in severe GI side effects. • Early September 2026. Study: Animal Study #1 (GLP-1-A26-1) What Big Pharma is Watching: Performance results of alternative novel DehydraTECH formulations designed to completely bypass or optimize traditional, erratic SNAC-inclusive carriers. 10x minimum setup potential 🚀 $VKTX $LLY $NVO

0 · Reply

Market Cap	15.77M
Revenue (ttm)	710,000.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,676.06%
Debt to Equity Ratio	0.00

Volume	131,200
Avg Vol	94,674
Day's Range	N/A - N/A
Shares Out	24.79M
Stochastic %K	73%
Beta	0.34
Analysts	Strong Sell
Price Target	$3.75